BiotechTube

Losmapimod + Placebo oral tablet

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions

Facioscapulohumeral Muscular Dystrophy (FSHD)

Trial Timeline

Jun 16, 2022 → Nov 19, 2024

NCT ID
NCT05397470

About Losmapimod + Placebo oral tablet

Losmapimod + Placebo oral tablet is a phase 3 stage product being developed by Fulcrum Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is terminated. This product is registered under clinical trial identifier NCT05397470. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).

What happened to similar drugs?

0 of 1 similar drugs in Facioscapulohumeral Muscular Dystrophy (FSHD) were approved

Approved (0) Terminated (0) Active (1)
🔄AOC-1020 + PlaceboAvidity BiosciencesPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05397470Phase 3Terminated

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)

See all competitors
ProductCompanyStageHype Score
ACE-083 + ACE-083 or placeboMerckPhase 2
27
ACE-083MerckPhase 2
27
Placebo + RO7204239RochePhase 2
39
AOC-1020 + PlaceboAvidity BiosciencesPhase 3
44
Apitegromab + PlaceboScholar Rock HoldingPhase 2
39
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
25
LosmapimodFulcrum TherapeuticsPhase 2
17
LosmapimodFulcrum TherapeuticsPhase 2
17
ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22
Placebo + ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22